EP1532241A4 - Rationell konstruierte, von chondroitinase b abgeleitete lyasen - Google Patents

Rationell konstruierte, von chondroitinase b abgeleitete lyasen

Info

Publication number
EP1532241A4
EP1532241A4 EP03756399A EP03756399A EP1532241A4 EP 1532241 A4 EP1532241 A4 EP 1532241A4 EP 03756399 A EP03756399 A EP 03756399A EP 03756399 A EP03756399 A EP 03756399A EP 1532241 A4 EP1532241 A4 EP 1532241A4
Authority
EP
European Patent Office
Prior art keywords
chondroitinase
rationally designed
polysaccharide lyases
inhibiting
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03756399A
Other languages
English (en)
French (fr)
Other versions
EP1532241A2 (de
EP1532241B1 (de
Inventor
Kevin Pojasek
Rahul Raman
Ram Sasisekharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of EP1532241A2 publication Critical patent/EP1532241A2/de
Publication of EP1532241A4 publication Critical patent/EP1532241A4/de
Application granted granted Critical
Publication of EP1532241B1 publication Critical patent/EP1532241B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Confectionery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EP03756399A 2002-06-03 2003-06-03 Rationell konstruierte, von chondroitinase b abgeleitete lyasen Expired - Lifetime EP1532241B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38550902P 2002-06-03 2002-06-03
US385509P 2002-06-03
PCT/US2003/017680 WO2003102160A2 (en) 2002-06-03 2003-06-03 Rationally designed polysaccharide lyases derived from chondroitinase b

Publications (3)

Publication Number Publication Date
EP1532241A2 EP1532241A2 (de) 2005-05-25
EP1532241A4 true EP1532241A4 (de) 2005-12-14
EP1532241B1 EP1532241B1 (de) 2010-09-15

Family

ID=29712183

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03756399A Expired - Lifetime EP1532241B1 (de) 2002-06-03 2003-06-03 Rationell konstruierte, von chondroitinase b abgeleitete lyasen

Country Status (7)

Country Link
US (4) US6962699B2 (de)
EP (1) EP1532241B1 (de)
AT (1) ATE481478T1 (de)
AU (1) AU2003243396A1 (de)
CA (1) CA2493509C (de)
DE (1) DE60334220D1 (de)
WO (1) WO2003102160A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566406B1 (en) * 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
WO2000012726A2 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
CA2643162C (en) 1999-04-23 2018-01-02 Massachusetts Institute Of Technology Polymer identification, compositional analysis and sequencing, based on property comparison
EP1266013B1 (de) * 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii und deren verwendungen
US7083937B2 (en) 2000-09-12 2006-08-01 Massachusetts Institute Of Technology Methods and products related to the analysis of polysaccarides
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
EP1575534B1 (de) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase und ihre verwendungen
AU2003304173A1 (en) 2002-05-04 2005-01-04 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
EP1590648A4 (de) * 2002-05-20 2007-04-18 Massachusetts Inst Technology Neues verfahren zur sequenzbestimmung mittels nmr
EP1532241B1 (de) * 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
US20060153827A1 (en) * 2002-08-15 2006-07-13 Gruskin Elliott A Chimeric protein
JP4606712B2 (ja) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
WO2004110360A2 (en) 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
WO2004103299A2 (en) * 2003-05-16 2004-12-02 Acorda Therapeutics, Inc. Compositions and methods for the treatment of cns injuries
AU2016204464B2 (en) * 2003-05-16 2018-03-22 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
WO2005000219A2 (en) * 2003-05-28 2005-01-06 The Board Of Trustees Of The University Of Illinois Composition for blocking hiv binding to dendritic cells and methods of use thereof
WO2005087920A2 (en) * 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
AU2005244933B2 (en) 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
AU2006294755B2 (en) 2005-09-26 2012-04-19 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
US20080071148A1 (en) * 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
ES2642088T3 (es) 2006-10-10 2017-11-15 Acorda Therapeutics, Inc. Composiciones y métodos de uso de mutantes de condroitinasa ABCI
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
EP2150616A4 (de) 2007-05-10 2011-07-27 Univ Arizona Geregelte antigensynthese und/oder geregelte attenuation zur verbesserung der impfstoff immunogenität und/oder -sicherheit
GB0712302D0 (en) * 2007-06-22 2007-08-01 Cambridge Entpr Ltd Chrondroitinase polypeptides
US20090286289A1 (en) * 2008-03-10 2009-11-19 Pang Danny Z Production of Hyaluronate Unsaturated Disaccharides and its Application
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9796970B1 (en) 2017-04-24 2017-10-24 Advantek Serum Laboratories Ltd. Production of high purity chondroitinase ABC
CN111593040B (zh) * 2020-06-20 2022-08-30 山东大学 硫酸皮肤素裂解酶及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US197933A (en) * 1877-12-11 Improvement in wood-screws
US99628A (en) * 1870-02-08 Signors to themselves and a
US37376A (en) * 1863-01-06 Improvement in breech-loading fire-arms
US128225A (en) * 1872-06-25 Improvement in workmen s time-registers
US92037A (en) * 1869-06-29 Improved shoe-pegging- machine
US204869A (en) * 1878-06-11 Improvement in weighing-scales
US91471A (en) * 1869-06-15 steigmeyer
US91472A (en) * 1869-06-15 Improvement in plows
US169143A (en) * 1875-10-26 Improvement in perforating stamps
US8820A (en) * 1852-03-23 Improvement in friction-primers for cannon
US191587A (en) * 1877-06-05 Improvement in piano-forte bridges
US122793A (en) * 1872-01-16 Improvement in air-supplying attachments for stoves
JPS6031478B2 (ja) 1978-02-10 1985-07-22 生化学工業株式会社 純コンドロイチナ−ゼｂの製造法
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
JP2726275B2 (ja) 1988-08-24 1998-03-11 生化学工業株式会社 グリコサミノグリカン分解酵素の精製法
JPH0693836B2 (ja) * 1988-11-25 1994-11-24 新技術事業団 バチルス属に属するヘパリナーゼ生産微生物、新規ヘパリナーゼ及びその製法
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
JPH04270327A (ja) * 1991-02-26 1992-09-25 Fuji Photo Optical Co Ltd カメラの露出補正装置
JP3110064B2 (ja) * 1991-03-06 2000-11-20 生化学工業株式会社 新規ヘパリチナーゼ、その製造法及びその生産菌
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
US5668274A (en) 1991-04-23 1997-09-16 Akzo Nobel N.V. Sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US5773277A (en) 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
US6001630A (en) * 1992-06-26 1999-12-14 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Pharmaceutical compositions of chondroitinase ABC isolated from Proteus vulgaris ATCC 6896
JP3419811B2 (ja) 1993-02-24 2003-06-23 マルハ株式会社 コンドロイチナーゼ遺伝子
US5389539A (en) * 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5578480A (en) 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
RU2153506C2 (ru) 1993-09-30 2000-07-27 Сейкагаку когио кабусики кайся Дерматансульфат или его соль, противотромбозные средства, способ предупреждения или лечения тромбозов, способ предупреждения или лечения синдрома рассеянной интраваскулярной коагуляции, способ лечения инфаркта миокарда
EP0726773A1 (de) 1993-11-17 1996-08-21 Massachusetts Institute Of Technology Verfahren zur hemmung der angiogenese mittels heparinase
US5498536A (en) 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
JPH10500843A (ja) 1994-04-22 1998-01-27 アメリカン・サイアナミド・カンパニー コンドロイチナーゼｉおよびｉｉ、その製造法および用途
US5525500A (en) 1994-04-22 1996-06-11 American Cyanamid Company Chromatographic process for the copurification of chondroitinase I and II proteins from Proteus vulgaris
US5681733A (en) * 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) * 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5965507A (en) 1995-06-08 1999-10-12 Procter & Gamble Company Cleaning compositions comprising chondroitinase
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
IT1285546B1 (it) 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
DE69829605T2 (de) 1997-05-02 2006-02-09 Seikagaku Corp. Chondroitinase enthaltende Zusammensetzungen
AU735216B2 (en) 1997-08-22 2001-07-05 Seikagaku Corporation Therapeutic agent for herniated intervertebral disc
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6378527B1 (en) * 1998-04-08 2002-04-30 Chondros, Inc. Cell-culture and polymer constructs
WO1999058650A1 (en) 1998-05-13 1999-11-18 Biomarin Pharmaceuticals Lytic enzymes useful for treating fungal infections
JP2000044601A (ja) 1998-07-29 2000-02-15 Seikagaku Kogyo Co Ltd 新規ガラクトサミノグリカン
CA2643162C (en) 1999-04-23 2018-01-02 Massachusetts Institute Of Technology Polymer identification, compositional analysis and sequencing, based on property comparison
AU1608701A (en) 1999-11-12 2001-06-06 Biomarin Pharmaceutical Inc. Lytic enzymes useful for treating fungal infections
WO2001035977A2 (en) 1999-11-17 2001-05-25 Ibex Technologies, Inc. Attenuation of tumor growth, metastasis and angiogenesis by use of chondroitin sulfate degrading enzymes
WO2001038399A1 (fr) 1999-11-24 2001-05-31 Seikagaku Corporation Procede de traitement des maladies des tissus superficiels
WO2001039795A2 (en) 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
ATE357506T1 (de) 2000-01-21 2007-04-15 Biomarin Pharm Inc Flavobakterium heparinum expressions-system
EP1266013B1 (de) * 2000-03-08 2014-10-15 Massachusetts Institute Of Technology Heparinase iii und deren verwendungen
US7083937B2 (en) 2000-09-12 2006-08-01 Massachusetts Institute Of Technology Methods and products related to the analysis of polysaccarides
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20030008820A1 (en) 2001-03-27 2003-01-09 Massachusetts Institute Of Technology Methods and products related to FGF dimerization
US20040214228A9 (en) 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
US20030096281A1 (en) 2001-09-14 2003-05-22 Ganesh Venkataraman Methods of making glycomolecules with enhanced activities and uses thereof
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
AU2003225724A1 (en) 2002-03-11 2003-09-29 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
EP1551852A4 (de) 2002-04-25 2007-03-21 Momenta Pharmaceuticals Inc Verfahren und produkte zur verabreichung an die schleimhaut
EP1575534B1 (de) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase und ihre verwendungen
EP1590648A4 (de) 2002-05-20 2007-04-18 Massachusetts Inst Technology Neues verfahren zur sequenzbestimmung mittels nmr
EP1532241B1 (de) 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
JP2006515927A (ja) 2002-12-20 2006-06-08 モメンタ ファーマシューティカルズ インコーポレイテッド 疾患を診断および監視するためのグリカンマーカー
JP4606712B2 (ja) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
KR100846449B1 (ko) * 2003-03-27 2008-07-16 삼성전자주식회사 휴대용 복합장치의 웹 카메라 모드 설정방법
WO2004110360A2 (en) 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7407810B2 (en) 2003-09-04 2008-08-05 Momenta Pharmaceuticals, Inc. Methods and apparatus for characterizing polymeric mixtures
US7851223B2 (en) 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
CA2558263A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
AU2005244933B2 (en) 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ACHUR RAJESHWARA N ET AL: "Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 51, 22 December 2000 (2000-12-22), pages 40344 - 40356, XP002348575, ISSN: 0021-9258 *
DAIDOUJI KOUICHI ET AL: "Neoplastic changes in saccharide sequence of dermatan sulfate chains derived from human colon cancer", DIGESTIVE DISEASES AND SCIENCES, vol. 47, no. 2, February 2002 (2002-02-01), pages 331 - 337, XP002348577, ISSN: 0163-2116 *
DATABASE EMBL [online] 3 October 1995 (1995-10-03), "Pedobacter heparinus chondroitinase B precursor (cslB) gene, complete cds.", XP002348555, retrieved from EBI accession no. EM_PRO:CH27584 Database accession no. CH27584 *
GU KENAN ET AL: "Purification, characterization and specificity of chondroitin lyases and glucuronidase from Flavobacterium heparinum", BIOCHEMICAL JOURNAL, vol. 312, no. 2, 1995, pages 569 - 577, XP002348573, ISSN: 0264-6021 *
MASCELLANI GIUSEPPE ET AL: "Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate", BIOCHEMICAL JOURNAL, vol. 296, no. 3, 1993, pages 639 - 648, XP002348574, ISSN: 0264-6021 *
MONAGLE PAUL ET AL: "Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes: Characterization of novel anticoagulants", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 50, 11 December 1998 (1998-12-11), pages 33566 - 33571, XP002348576, ISSN: 0021-9258 *
PLAAS ANNA H K ET AL: "Glycosaminoglycan sulfation in human osteoarthritis: Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate", 15 May 1998, JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, PAGE(S) 12642-12649, ISSN: 0021-9258, XP002339999 *
POJASEK K ET AL: "Recombinant expression, purification, and kinetic characterization of chondroitinase AC and chondroitinase B from Flavobacterium heparinum.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 17 AUG 2001, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 343 - 351, XP002348572, ISSN: 0006-291X *
TKALEC ANA LYDIA ET AL: "Isolation and expression in Escherichia coli of cslA and cslB, genes coding for the chondroitin sulfate-degrading enzymes chondroitinase AC and chondroitinase B, respectively, from Flavobacterium heparinum", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 66, no. 1, January 2000 (2000-01-01), pages 29 - 35, XP002348550, ISSN: 0099-2240 *

Also Published As

Publication number Publication date
US20050233419A1 (en) 2005-10-20
WO2003102160A2 (en) 2003-12-11
CA2493509C (en) 2010-03-09
US6962699B2 (en) 2005-11-08
AU2003243396A1 (en) 2003-12-19
US7129335B2 (en) 2006-10-31
ATE481478T1 (de) 2010-10-15
DE60334220D1 (de) 2010-10-28
AU2003243396A8 (en) 2003-12-19
WO2003102160A3 (en) 2004-09-16
CA2493509A1 (en) 2003-12-11
US20050227320A1 (en) 2005-10-13
US7105334B2 (en) 2006-09-12
US20040091472A1 (en) 2004-05-13
EP1532241A2 (de) 2005-05-25
EP1532241B1 (de) 2010-09-15
US20070065424A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
AU2003243396A8 (en) Rationally designed polysaccharide lyases derived from chondroitinase b
WO2001066772A3 (en) Heparinase iii and uses thereof
WO2002023190A3 (en) Methods and products related to low molecular weight heparin
WO2005087920A3 (en) Recombinant chondroitinase abc i and uses thereof
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
NO20055722D0 (no) Antiseptiske preparater, fremgangsmater og systemer
ATE277157T1 (de) Reinigungsverfahren zur stärkeentfernung
MY148405A (en) Immunogenic composition
AU2001275651A1 (en) Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
DE60332168D1 (de) Adaptives filtersystem für reklamenachrichten
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
MX345967B (es) Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
IL145557A (en) Immunoabsorber for use in sepsis therapy
DE60334489D1 (de) Kokzidioseimpfstoff sowie verfahren zu seiner herstellung und verwendung
NO20015986D0 (no) Produktet chitosan, samt fremstillingsmetode og anvendelse av chitosan
AU2385095A (en) Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
AU2235802A (en) Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation
AU2001265828A1 (en) Steeping process
KR100695778B1 (ko) 푸코이단을 생산하는 미생물 및 이를 이용한 푸코이단의생산 방법
GB0207008D0 (en) Chemically modified polysaccharides II
AU2003299123A1 (en) Reaction products of 2-propylheptanol with 1-halogen-2,3-epoxypropanes and 1-hydroxy-2,3-epoxypropane
MXPA02003693A (es) Verificacion de la actividad de los inhibidores del factor xa.
ATE400279T1 (de) Verwendung der sulfatierten polysacchariden zur behandlung von thrombosen
PL1658494T3 (pl) Sposób miareczkowania in vitro NTCA i jego zastosowanie w sposobie oceny i/lub kontroli sposobu wytwarzania produktu biologicznego

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041231

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20051028

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SASISEKHARAN, RAM

Inventor name: RAMAN, RAHUL

Inventor name: POJASEK, KEVIN

17Q First examination report despatched

Effective date: 20090126

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60334220

Country of ref document: DE

Date of ref document: 20101028

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110117

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101226

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60334220

Country of ref document: DE

Effective date: 20110616

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110603

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100915

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200629

Year of fee payment: 18

Ref country code: FR

Payment date: 20200625

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20200629

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60334220

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210603

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210630